<\/p>\n
NEW FILINGS<\/p>\n
Company: AMTD International Inc.
\nSymbol: TBD
\nDescription: They are a leading Hong Kong-headquartered comprehensive financial institution.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): AMTD Global Markets, Tiger Global
\nFiled: 6-20-19
\nListed Cash Raise: $200m<\/p>\n
Company: Medallia, Inc.
\nSymbol: MDLA
\nDescription: They created a new category of enterprise software, experience management, and they are the market leader.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): BofA Merrill Lynch, Citigroup, Wells Fargo Securities Credit Suisse
\nCo-Manager(s): Oppenheimer, William Blair, Needham, Craig Hallum Capital Group, Roth Capital
\nFiled: 6-21-19
\nListed Cash Raise: $100m<\/p>\n
Company: Phreesia, Inc.
\nSymbol: PHR
\nDescription: They are a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): JP Morgan, Wells Fargo Securities, William Blair, Allen & Co., Piper Jaffray
\nFiled: 6-21-19
\nListed Cash Raise: $125m<\/p>\n
Company: Fulcrum Therapeutics, Inc.
\nSymbol: FULC
\nDescription: They are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch, SVB Leerink
\nFiled: 6-21-19
\nListed Cash Raise: $86.25m<\/p>\n
Company: Mirum Pharmaceuticals, Inc.
\nSymbol: MIRM
\nDescription: They are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Citigroup, Evercore ISI, Guggenheim Securities
\nCo-Manager(s): Raymond James, Roth Capital
\nFiled: 6-21-19
\nListed Cash Raise: $86.25m<\/p>\n
TERMS ADDED<\/p>\n
Company: Karuna Therapeutics, Inc
\nSymbol: KRTX
\nDescription: They are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need.
\nShares: 4.375 million
\nPrice Range: $15.00-$17.00
\nMarket Cap: $320m-$365m
\nTrade Date: Friday, 6\/28
\nUnderwriter(s): Goldman Sachs, Citigroup, Wells Fargo
\nCo-Manager(s): Wedbush PacGrow
\nTerms Added: 6-17-19<\/p>\n
Company: BridgeBio Pharma, Inc.
\nSymbol: BBIO
\nDescription: They are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source.
\nShares: 15 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $1.6bn-$1.85bn
\nTrade Date: Thursday, 6\/27
\nUnderwriter(s): J.P. Morgan, Goldman Sachs & Co, Jefferies, SVB Leerink, KKR
\nCo-Manager(s): Piper Jaffray, Mizuho Securities, BMO Capital Markets, Raymond James
\nTerms Added: 6-17-19<\/p>\n
Company: Adaptive Biotechnologies Corporation
\nSymbol: ADPT
\nDescription: They are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
\nShares: 12.5 million
\nPrice Range: $15.00-$17.00
\nMarket Cap: $1.8bn-$2.0bn
\nTrade Date: Thursday, 6\/27
\nUnderwriter(s): Goldman Sachs & Co., J.P. Morgan, BofA Merrill Lynch
\nCo-Manager(s): Cowen, Guggenheim, William Blair, BTIG
\nTerms Added: 6-17-19<\/p>\n
Company: The RealReal, Inc.
\nSymbol: REAL
\nDescription: The RealReal is the world\u2019s largest online marketplace for authenticated, consigned luxury goods.
\nShares: 15 million
\nPrice Range: $17.00-$19.00
\nMarket Cap: $1.4b-$1.57bn
\nTrade Date: Friday, 6\/28
\nUnderwriter(s): Credit Suisse, BofA Merrill Lynch, UBS Investment Bank
\nCo-Manager(s): KeyBanc Capital, Stifel, Cowen, Raymond James
\nTerms Added: 6-17-19<\/p>\n
Company: Priam Properties Inc.
\nSymbol: PRMI
\nDescription: They are a newly formed, self-administered and self-managed real estate investment company focused on acquiring, improving, owning and managing multi-tenant office properties in high-growth urban nodes in the Midwest and Southeast United States.
\nShares: 9 million
\nPrice Range: $18.00-$20.00
\nMarket Cap: $160m-$180m
\nTrade Date: Thursday, 6\/27
\nUnderwriter(s): BofA Merrill Lynch, Baird, RBC Capital
\nCo-Manager(s): Stifel, BB&T Capital Markets, DA Davidson, Janney Montgomery Scott
\nTerms Added: 6-17-19<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,1536],"tags":[],"class_list":["post-8800","post","type-post","status-publish","format-standard","hentry","category-ipo","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/8800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=8800"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/8800\/revisions"}],"predecessor-version":[{"id":8807,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/8800\/revisions\/8807"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=8800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=8800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=8800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}